L3VLUP
ProSign in

SYK · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

SYKJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • SYK
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterSYKJNJ
Q3 202019 holders, $10.7bn30 holders, $26.2bn
Q4 202015 holders, $13.5bn32 holders, $26.6bn
Q1 202121 holders, $14.0bn31 holders, $25.3bn
Q2 202120 holders, $15.4bn37 holders, $25.6bn
Q3 202120 holders, $15.9bn40 holders, $24.1bn
Q4 202122 holders, $15.9bn33 holders, $25.2bn
Q1 202221 holders, $16.1bn35 holders, $28.2bn
Q2 202221 holders, $11.4bn33 holders, $26.9bn
Q3 202214 holders, $12.1bn36 holders, $25.4bn
Q4 202215 holders, $14.5bn35 holders, $27.6bn
Q1 202317 holders, $17.5bn42 holders, $24.5bn
Q2 202323 holders, $16.9bn38 holders, $25.0bn
Q3 202321 holders, $14.0bn37 holders, $18.9bn
Q4 202322 holders, $14.9bn31 holders, $19.0bn
Q1 202424 holders, $16.9bn32 holders, $19.7bn
Q2 202423 holders, $15.3bn35 holders, $20.4bn
Q3 202420 holders, $15.5bn28 holders, $22.3bn
Q4 202421 holders, $14.8bn37 holders, $20.4bn
Q1 202518 holders, $14.8bn32 holders, $20.5bn
Q2 202521 holders, $16.8bn31 holders, $18.4bn
Q3 202523 holders, $15.1bn32 holders, $23.7bn
Q4 202525 holders, $14.0bn29 holders, $27.8bn
Q1 202629 holders, $14.0bn34 holders, $35.6bn
Q2 202618 holders, $11.4bn33 holders, $39.1bn
SYK

Stryker Corporation

Holders
20
Reported value
$15.5bn
Buyers
7
Sellers
13

Breadth -6 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
28
Reported value
$22.3bn
Buyers
13
Sellers
16

Breadth -3 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only SYK (4)

Artisan Partners LP, D. E. Shaw & Co., Two Sigma Investments LP, Voloridge Investment Management LLC

Only JNJ (12)

Dodge & Cox, Eisler Capital Management Ltd, ExodusPoint Capital Management LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Man Group PLC, Markel Group Inc, Marshall Wace LLP, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, Two Sigma Advisers LP, Walleye Capital LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →